Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

- 1. (Currently Amended) A corneal implant comprising a <u>hydrated</u> membrane, said <u>hydrated</u> membrane comprising a <u>mixture of</u> a biological polymer and a polyacrylamide.
- 2. (Original) The implant of claim 1, wherein the polyacrylamide is a poly (N-alkylacrylamide).
- 3. (Original) The implant of claim 1, wherein the polyacrylamide is poly (N-isopropylacrylamide).
- 4. (Currently Amended) The implant of claim 1, wherein the biological polymer is selected from the group consisting of collagen, fibrin-fibrinogen, gelatin, glycoprotein, peptide, glycosaminoglycan, elastin and mixtures thereof.
- 5. (Original) The implant of claim 4, wherein the collagen is selected from the group consisting of telocollagen and atelocollagen.
- 6. (Withdrawn) The implant of claim 4, wherein the collagen is a type I collagen.
- 7. (Withdrawn) The implant of claim 4, wherein the collagen is selected from the group consisting of recombinant collagen and collagen from a natural source.
- 8. (Original) The implant of claim 1, wherein the biological polymer and polyacrylamide are present in a ratio of about 0.2:1.0 (w/w) to about 1.0:0.2 (w/w) biological polymer:polyacrylamide.
- 9. (Original) The implant of claim 8, wherein the biological polymer and polyacrylamide are present in a ratio of about 0.3:1.0 (w/w) biological polymer:polyacrylamide.
- 10. (Original) The implant of claim 1, wherein said membrane further comprises a chemical crosslink.

- 11. (Original) The implant of claim 10, wherein the crosslink is obtained by crosslinking with a crosslinking agent selected from the group consisting of (a) a carbodiimide crosslinking agent; (b) an N-hydroxysuccinimide; and (c) both (a) and (b).
- 12. (Original) The implant of claim 11, wherein the carbodiimide crosslinking agent is 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide.
- 13. (Original) The implant of claim 1, wherein the membrane has a thickness of about 20 μm to about 400 μm .
- 14. (Original) The implant of claim 13, wherein the membrane has a thickness of about 50 μ m to about 100 μ m.
- 15. (Original) The implant of claim 1, wherein said implant comprises a plurality of membranes, wherein at least one of said plurality of membranes comprises a biological polymer and a polyacrylamide.
- 16. (Canceled).
- 17. (Canceled).
- 18. (Canceled).
- 19. (Canceled).
- 20. (Canceled).
- 21. (Canceled).
- 22. (Canceled).
- 23. (Canceled).
- 25. (Currently Amended) A method of treating a condition characterized by a corneal defect, said method comprising applying the implant of claim 1 to said <u>a</u> subject.
- 26. (Currently Amended) The method of claim 25, wherein said subject is <u>a</u> human.

- 27. (Original) A commercial package comprising the implant of claim 1, together with instructions for treating a condition characterized by a corneal defect.
- 28. (New) A commercial package comprising:
- a corneal implant comprising a dried membrane, said dried membrane comprising a mixture of a biological polymer and a polyacrylamide; and
- a rehydration solution for use prior to implantation of the dried membrane.
- 29. (New) A corneal implant comprising a membrane, said membrane comprising a mixture of a biological polymer and a polyacrylamide, wherein the membrane has an elastic modulus of less than about 10 MPa, a tensile strength at break of less than 6MPa, an elongation at break of less than 80% and a tensile energy to break of less than 2 mJ.
- 30. (New) The implant of claim 1, wherein the membrane is hydrated with a solution comprising a drug, a bioactive compound, or a combination thereof.
- 31. (New) The implant of claim 30, wherein the bioactive compound is selected from the group consisting of glycoproteins, adhesive peptides, glycosaminoglycans, lipids, cytokines, chemokines and mixtures thereof.
- 32. (New) The implant of claim 1, wherein the mixture of the biological polymer and the polyacrylamide further comprise a drug, a bioactive compound, or a combination thereof.
- 33. (New) The implant of claim 32, wherein the bioactive compound is selected from the group consisting of glycoproteins, adhesive peptides, glycosaminoglycans, lipids, cytokines, chemokines and mixtures thereof.